Invasion of host erythrocytes is essential to the life cycle of Plasmodium parasites and development of the pathology of malaria. The stages of erythrocyte invasion, including initial contact, apical reorientation, junction formation, and active invagination, are directed by coordinated release of specialized apical organelles and their parasite protein contents 1 . Among these proteins, and central to invasion by all species, are two parasite protein families, the reticulocyte-binding protein homologue (RH) and erythrocyte-binding like proteins, which mediate host-parasite interactions 2 . RH5 from Plasmodium falciparum (PfRH5) is the only member of either family demonstrated to be necessary for erythrocyte invasion in all tested strains, through its interaction with the erythrocyte surface protein basigin (also known as CD147 and EMMPRIN) 3,4 . Antibodies targeting PfRH5 or basigin efficiently block parasite invasion in vitro 4-9 , making PfRH5 an excellent vaccine candidate. Here we present crystal structures of PfRH5 in complex with basigin and two distinct inhibitory antibodies. PfRH5 adopts a novel fold in which two three-helical bundles come together in a kite-like architecture, presenting binding sites for basigin and inhibitory antibodies at one tip. This provides the first structural insight into erythrocyte binding by the Plasmodium RH protein family and identifies novel inhibitory epitopes to guide design of a new generation of vaccines against the blood-stage parasite.
Invasion of host erythrocytes is essential to the life cycle of Plasmodium parasites and development of the pathology of malaria. The stages of erythrocyte invasion, including initial contact, apical reorientation, junction formation, and active invagination, are directed by coordinated release of specialized apical organelles and their parasite protein contents 1 . Among these proteins, and central to invasion by all species, are two parasite protein families, the reticulocyte-binding protein homologue (RH) and erythrocyte-binding like proteins, which mediate host-parasite interactions 2 . RH5 from Plasmodium falciparum (PfRH5) is the only member of either family demonstrated to be necessary for erythrocyte invasion in all tested strains, through its interaction with the erythrocyte surface protein basigin (also known as CD147 and EMMPRIN) 3, 4 . Antibodies targeting PfRH5 or basigin efficiently block parasite invasion in vitro [4] [5] [6] [7] [8] [9] , making PfRH5 an excellent vaccine candidate. Here we present crystal structures of PfRH5 in complex with basigin and two distinct inhibitory antibodies. PfRH5 adopts a novel fold in which two three-helical bundles come together in a kite-like architecture, presenting binding sites for basigin and inhibitory antibodies at one tip. This provides the first structural insight into erythrocyte binding by the Plasmodium RH protein family and identifies novel inhibitory epitopes to guide design of a new generation of vaccines against the blood-stage parasite.
Each Plasmodium species contains at least one RH protein. These are often large, of low sequence complexity and with no homology to proteins of known structure. PfRH5 is unusual in being significantly shorter than its homologues (,60 kDa for PfRH5 vs 200-375 kDa for other RH proteins). It lacks their carboxy-terminal transmembrane segment, but associates peripherally with the membrane and with PfRH5 interacting protein (PfRipr) 10 . Although it shares only ,20% pairwise sequence identity with other PfRH proteins 3, 11 , PfRH5 is remarkably conserved, with only five common non-synonymous single nucleotide polymorphisms (SNPs) 7, 8, 12 . Crucially, antibodies raised against one PfRH5 variant neutralise parasites of all tested heterologous strains, containing these and other less common SNPs 6, 8, 9 , and anti-PfRH5 monoclonal antibodies that prevent parasite growth in vitro can directly block the PfRH5-basigin interaction 5 . Moreover, acquisition of anti-PfRH5 antibodies during natural infection correlates with clinical outcome and these antibodies can also inhibit parasite growth in vitro 13 . These findings have generated intense excitement about PfRH5 as a next-generation blood-stage malaria vaccine target and emphasized the need for structural information to guide rational immunogen design.
Structural studies of PfRH5 required a protein construct lacking flexible regions but still capable of binding basigin. Long disordered regions were predicted within residues 1-140 and 248-296 (Extended Data Fig. 1a ), and in cultured parasite lines, PfRH5 is processed by removal of the amino terminus to generate a ,45 kDa fragment 3, 10 . We therefore designed PfRH5DNL, encompassing residues 140-526 but lacking 248-296, and showed that it binds basigin by surface plasmon resonance with an affinity of 1.3 mM ( Fig. 1c ), comparable to the affinity of fulllength PfRH5 for basigin (1.1 mM) 4 .
To ensure that PfRH5DNL contains epitopes required to elicit an inhibitory immune response, we raised rabbit polyclonal IgG and tested their ability to neutralise parasites by a growth-inhibitory activity (GIA) assay ( Fig. 1d ). IgG raised against PfRH5DNL protein showed a potent inhibitory effect, similar to that of IgG raised by immunisation of rabbits with viral vectors expressing full-length PfRH5 6 , or full-length PfRH5 recombinant protein 8, 9 . We also tested binding of PfRH5DNL to a panel of mouse monoclonal antibodies previously characterized for PfRH5 binding and growth-inhibitory activity 5 . PfRH5DNL bound to growthinhibitory antibodies including QA1, QA5 and 9AD4, but not to noninhibitory 4BA7 and RB3 (Extended Data Fig. 2 ). Thus, PfRH5DNL induces a growth-inhibitory immune response, and contains the epitopes targeted by inhibitory antibodies.
For structural studies, PfRH5DNL was mixed with basigin or fragments of growth-inhibitory monoclonal antibodies, 9AD4 or QA1. The complexes were trimmed using endoproteinase GluC and lysines chemically methylated before crystallization. Crystals formed and data were collected to 3.1 Å (PfRH5DNL-basigin), 2.3 Å (PfRH5DNL-9AD4) and 3.1 Å resolution (PfRH5DNL-QA1). Structures were determined using molecular replacement (Extended Data Table 1 ). PfRH5 adopts a rigid, flat, 'kite-shaped' architecture with a pseudotwofold rotation symmetry and no similarity to known structures ( Fig. 1a ). Each half is predominantly built from a three-helical bundle, with the outermost helices containing significant kinks or breaks. The N-terminal half begins with a short, two-stranded b-sheet that crosses the long axis of the kite at its centre. This is followed by a single, short helix and two long, kinked helices connected by the truncated loop (containing 58 residues in full-length PfRH5). The C-terminal half is simpler, consisting of three long helices that span the entire length of the domain and finishing with a flexible C terminus. One disulphide bond (C345-C351) stabilizes the loop that links the two halves of the structure, while another links the second and third helices (C224-C317), leaving one unpaired cysteine (C329).
PfRH5 is predominantly rigid, with five copies in the three different crystal forms aligning with an r.m.s.d. of 0.9 Å over 95% of residues (Extended Data Fig. 1b ). Only the C terminus (residues 496-end) and the loop linking helices 4 and 5 (residues 396-406) adopt different positions in different crystal forms. A molecular envelope derived from small angle X-ray scattering (SAXS) analysis of full-length PfRH5 in solution exhibits a similar flat structure ( Fig. 1b , Extended Data Fig. 3 ). This envelope is elongated relative to PfRH5DNL, most probably owing to residues missing in this construct or not ordered in the crystal structure (22 residues at the C terminus, the flexible loop, and perhaps part of the extended N terminus).
As members of the Plasmodium RH family share little sequence identity, sequence alignments and structure-based threading were used to predict whether other members contain the PfRH5 fold. In each protein analysed (P. falciparum RH1, RH2a, RH2b, RH3 and RH4; Plasmodium vivax RBP-1 and RBP-2; Plasmodium reichenowi RH5; and Plasmodium yoelii Py01365), N-terminal PfRH5-like domains were identified with high confidence, despite sequence identities of 14-22% and a lack of totally conserved residues or disulphide bonds (Extended Data Fig. 4a ). Similar residues are located primarily in the interior of the domain, where they may stabilize the fold (Extended Data Fig. 4b ). In PfRH4, the only other RH protein with a known erythrocyte receptor, the complement receptor 1 (CR1) binding fragment contains the putative PfRH5 fold 14 . These PfRH5-like domains are therefore excellent candidates for ligand-binding modules in other RH proteins.
Basigin binds at the tip of PfRH5, distant from the flexible loop and C terminus, with both domains and the intervening linker directly contacting PfRH5 ( Fig. 2a, d ). Most of the contact area (,1,350 Å 2 ) occurs through hydrogen bonds between the backbone of strands A and G of the basigin N-terminal domain and loops at the tip of PfRH5 (Extended Data Table 2a ). PfRH5 residues F350 and W447 stabilize this interaction by packing into hydrophobic pockets on basigin. The limited involvement of basigin side chains will reduce the potential for basigin escape mutants that prevent PfRH5 binding and impair parasite invasion.
The basigin C-terminal domain and H102 in the linker also directly contact PfRH5 (Extended Data Table 2a ). The three loops at the tip of the basigin C-terminal domain (linking strands B and C, strands D and E and strands F and G) interact with the second and fourth helices of PfRH5 through hydrogen bonds and a hydrophobic patch contributed by residues VPP from the BC loop. However, flexibility of the basigin linker allows different orientations of the C-terminal domains in the two copies in the asymmetric unit of the crystal. Chain B interacts through the BC and DE loops (a ,650 Å 2 interface) while chain D interacts through the BC and FG loops (,480 Å 2 ) ( Fig. 2b ), leading to a maximum 
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difference of ,18 Å in the position of the C terminus in the two complexes. Flexibility is also predicted from SAXS analysis of the complex in solution (Extended Data Fig. 3 ). While PfRH5 and the basigin N-terminal domain fit the SAXS envelope, the C-terminal domain only partially fits, consistent with a flexible interaction with PfRH5. PfRH5 is highly conserved, with just twelve non-synonymous SNPs found in 227 field isolates, and only five at frequencies of 10% or greater 7, 8, 12 . These SNPs are distributed across the structure, but do not affect residues that directly contact basigin (Extended Data Fig. 5 ). By contrast, in sequenced laboratory strains, eight PfRH5 SNPs are associated with increased ability to invade Aotus erythrocytes 15, 16 . A number of these (I204, N347, Y358 and E362) are in or close to the basigin binding site, and may affect host tropism. Basigin residues which, when mutated, affect PfRH5 affinity (F27 and Q100) 17 are also located at the interface.
The two PfRH5-basigin complexes in the asymmetric unit pack together through basigin-mediated contacts, including a ,911 Å 2 interface between the two basigin C-terminal domains, bringing their C termini into close proximity (Extended Data Fig. 6 ). As yet, the role of PfRH5 in invasion is uncertain, but it is tempting to speculate that this 2:2 complex assembles during invasion, mediating a signalling event in either parasite or erythrocyte to trigger an essential downstream process. This would leave one face of PfRH5 available for binding of PfRipr 10 and other, as yet unidentified, binding partners. However, in solution (at concentrations # 24 mM) we observe no 2:2 complex, either through SAXS (Extended Data Fig. 3 ) or analytical ultracentrifugation ( Fig. 2c , Extended Data Fig. 7 ). Whether such a complex assembles at high local concentrations during invasion remains to be elucidated.
To identify inhibitory epitopes, complexes of PfRH5DNL with Fab fragments from three inhibitory monoclonal antibodies were studied by crystallography and SAXS. QA1 and QA5 were previously shown to block PfRH5-basigin binding and parasite growth. 9AD4 does not block PfRH5-basigin binding in vitro, but is one of the most effective antibodies currently available for inhibiting parasite growth 5 . Crystal structures of PfRH5 bound to QA1 and 9AD4 were confirmed by SAXS, while a model for PfRH5-QA5 was derived from SAXS analysis, guided by a previously identified linear epitope (residues 201-213 from helix 2) 5 .
The antibodies bind to three distinct sites, close to the vertex of PfRH5 (Fig. 3 , Extended Data Fig. 8 , Extended Data Table 2b , c). QA1 binds to loops at the PfRH5 tip, overlapping the basigin N-terminal domain binding site. QA5 predominantly interacts with PfRH5 helix 2, overlapping the basigin C-terminal domain binding site. In contrast, 9AD4 binds helices 2 and 3, close to, but not overlapping, either basigin binding site. This is likely to allow intact 9AD4 IgG to impede erythrocyte binding when PfRH5 and basigin are both membrane-tethered. This reveals inhibitory epitopes in or close to the basigin binding sites that can be targeted to block parasite invasion.
In summary, PfRH5 adopts a novel architecture formed, as in many families of parasite surface proteins 18 , from a robust a-helical scaffold. This maintains the overall fold by retaining residues required for helical packing, while allowing significant surface sequence variation. Sequence homology identifies this fold at the N terminus of other RH proteins, where it is likely to act as a ligand-binding module. Characterization of the PfRH5-basigin complex prompts a range of future experiments to investigate the role of PfRH5 in erythrocyte invasion. Furthermore, monoclonal antibodies that block parasite growth bind at or close to the basigin-binding site. Immunogens containing these regions of PfRH5 will be important components of a vaccine to prevent P. falciparum erythrocyte invasion, thereby crippling the parasite responsible for the deadliest form of human malaria. 

METHODS
Basigin cloning, expression and purification. A section of the basigin gene encoding immunoglobin domains 1 and 2 of the short isoform (residues 22-205) was amplified from complementary DNA using primers 59-CCGGATCCGCTGCCG GAACCGTGTTC-39 and 59-CCCATATGCTAGTGTGACCGCACTCTCAGG-39. PCR products were cloned into a modified pET15b vector (Novagen), which encodes an N-terminal hexa-histidine tag followed by a tobacco etch virus (TEV) protease cleavage site. TEV cleavage leaves an additional glycine at the N terminus from the cleavage site. Basigin was expressed in bacterial strain Origami B (DE3) (Novagen) by incubation overnight at 25 uC after induction with 1mM IPTG. The protein was purified by nickel-nitrilotriacetic acid (Ni 21 -NTA; Qiagen) affinity chromatography, followed by buffer exchange into PBS using a PD-10 desalting column (GE Healthcare), and overnight cleavage with His-tagged TEV protease at 4 uC, before a second Ni 21 -NTA column. The flow-through was concentrated using an Amicon Ultra centrifugal filter device (molecular mass cutoff, 3,000 Da). Finally, gel filtration was performed with a Superdex 200 16/60 column (GE Healthcare) in 20 mM HEPES (pH 7.5) and 150 mM NaCl. Expression and purification of 9AD4, QA1 and QA5. Anti-PfRH5 monoclonal antibodies were described previously 5 . Hybridomas expressing 9AD4, QA1 and QA5 were grown in Dulbecco's modified Eagle's medium (DMEM; Sigma) supplemented with 4 mM L-glutamine (Sigma), 0.01 M HEPES (Life Technologies), 100 U penicillin and 0.1 mg ml 21 streptomycin (Sigma), and 20% fetal calf serum (Gibco). They were then transferred into CD Hybridoma medium (Life Technologies) with glutamine, penicillin and streptomycin. The cells were harvested after 7-10 days. The cell culture supernatant was exchanged into 20 mM phosphate (pH 7.0) with a tangential flow filtration device (Pall).
The sample was then loaded onto a HiTrap Protein G HP column (GE Healthcare), eluted in 0.1 M glycine-HCl (pH 3.0), and immediately neutralised with 0.1 M Tris (pH 8.0). The sample was exchanged into 100 mM phosphate (pH 6.4), 300 mM NaCl, 2 mM EDTA, 5 mM L-cysteine (pH 6.4), and 1.5 mM b-mercaptoethanol using PD-10 columns (GE Healthcare).
Antibody fragments were generated by addition of papain agarose (Sigma), and overnight incubation at 37 uC. The papain agarose was removed by centrifugation, and the sample loaded onto a HiTrap Protein A HP column (GE Healthcare). The material that did not bind to the column was gel-filtered on a Superdex 200 16/60 column (GE Healthcare) in 20 mM HEPES (pH 7.5) and 150 mM NaCl. PfRH5 cloning, expression and purification. A synthetic gene was designed encoding full-length PfRH5 residues E26-Q526 from Plasmodium falciparum strain 7G8, codon optimised for expression in Drosophila melanogaster, with four putative glycosylation sites removed by mutation of threonines to alanines (Life Technologies). The gene was flanked by an EcoRI site and Kozak sequence at the 59 end, and a NotI site at the 39 end. Long-range disorder was predicted using POODLE-L 19 . A shortened mutant, PfRH5DN, lacking the flexible N terminus, was also synthesized, encompassing residues K140-Q526. A further mutant, PfRH5DNL, was generated by removal of a predicted disordered loop (residues N248-M296) in addition to the N-terminal truncation. All constructs contained a C-terminal hexa-histidine tag. PfRH5 constructs were subcloned into pExpreS 2 -1 (ExpreS 2 ion Biotechnologies, Horsholm, Denmark).
Constructs were transfected into Schneider 2 (S2) cells using ExpreS 2 Insect-TRx5 (ExpreS 2 ion) transfection reagent, and a polyclonal cell line was selected over three weeks in EX-CELL 420 insect cell media with L-glutamine (Sigma) supplemented with 10% fetal calf serum (Gibco) and 1.5 mg ml 21 zeocin. The stable cell lines were then expanded in EX-CELL 420 media without fetal calf serum or zeocin. Four days after the final split, the cells were harvested, and the cell culture supernatant exchanged into 20 mM phosphate, pH 7.4, 250 mM NaCl, 20 mM imidazole, and 0.005% Tween-20, using a tangential flow filtration device (Pall). Protein purification from the supernatant then proceeded through Ni 21 -NTA (HisTrap FF; GE Healthcare) and ConA lectin-binding chromatography (HiTrap ConA 4B; GE Healthcare).
Full-length PfRH5, PfRH5DN and PfRH5DNL for biophysical analysis were subjected to gel filtration on a Superdex 200 16/60 column (GE Healthcare), and concentrated with an Amicon centrifugal filter device (molecular weight cut-off, 10,000 Da).
To prepare PfRH5DNL for crystallization, the sample was cleaved overnight with endoproteinase GluC (Sigma) at 20 uC. At this point, basigin, 9AD4 or QA1 was added to the protein. To methylate the complex, 0.02 M dimethylamine-borane complex (ABC) and 0.04 M formaldehyde were added and the reaction incubated at 4 uC for 1 h. An additional 0.02 M ABC and 0.04 M formaldehyde were added; after another 1 h, 0.01 M ABC was added and the reaction was incubated at 4 uC overnight. Finally, the complexes were gel-filtered and concentrated as detailed above.
Surface plasmon resonance. Surface plasmon resonance experiments were carried out using a BIAcore T200 instrument (GE Healthcare). Experiments were performed at 20 uC in 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20, 2 mg ml 21 dextran, and 1 mg ml 21 salmon sperm DNA (Sigma Aldrich). Basigin was immobilized on a CM5 chip (GE Healthcare) by amine coupling (GE Healthcare kit) to a total of 850 RU. A concentration series of PfRH5DNL (8, 4, 2, 1, 0.5, 0.25, 0.125 and 0.0625 mM) was injected over the basigin-coated chip for 120 s at 30 ml min 21 , followed by a 300 s dissociation time. The chip surface was then regenerated with 30 s of 2 M NaCl. Specific binding of PfRH5DNL was obtained by subtracting the response from a blank surface from that of the basigin-coated surface. The kinetic sensorgrams were fitted to a global 1:1 interaction model, allowing determination of the dissociation constant, K D , using BIAevaluation software 1.0 (GE Healthcare). Assays of growth inhibition activity (GIA). Rabbit immunisations were carried out by Biogenes (Germany). Female ZiKa rabbits (n 5 4) were immunised intramuscularly with 20 mg PfRH5DNL protein formulated in complete Freund's adjuvant on day 0, followed by two booster immunisations intramuscularly on days 28 and 56 with the same dose of protein formulated in incomplete Freund's adjuvant. Control rabbits received the same immunisation schedule with 50 mg ovalbumin protein. Sera were collected two weeks after the final immunisation and shipped frozen.
Total IgG was purified from rabbit sera using protein G columns (Pierce). The P. falciparum 3D7 and 7G8 lines were maintained in continuous culture using fresh O 1 erythrocytes at 2% haematocrit and synchronised by two incubations in 5% sorbitol 6-8 h apart. Synchronised trophozoites were adjusted to 0.3% parasitaemia and then incubated for 42 h with the various IgG concentrations (tested in triplicate). Final parasitaemia was determined by biochemical determination of parasite lactate dehydrogenase 20 . Percentage growth inhibition is expressed relative to wells containing IgG from control immunised rabbits 6 . The mean of the three replicate wells was taken to obtain the final data for each individual rabbit at each tested IgG concentration. Experiments were performed twice against each strain of parasite with very similar results. A representative experiment is shown in Fig. 1d . The mean 6 standard error of mean are plotted for the results obtained with the purified IgG from the four immunised rabbits. ELISA. Maxisorp plates were coated with anti-PfRH5 mouse monoclonal antibody 5 (50 ml per well at 5 mg ml 21 ) and left at 4 uC overnight. Following six washes in PBS with 0.05% Tween-20 (PBS-T), plates were blocked with 150 ml per well Casein block solution (Pierce) for 1 h, followed by another six PBS-T washes. PfRH5DNL protein was added to wells in triplicate (50 ml per well) at four dilutions in blocking buffer (800, 200, 50 and 12.5 ng ml 21 ) and incubated at room temperature for 2 h. Following another six PBS-T washes, plates were incubated with polyclonal antifull-length PfRH5 rabbit serum 6 diluted 1:1,000 in blocking solution, 50 ml per well for 1 h. Following another PBS-T wash, plates were incubated with goat anti-rabbit IgG alkaline phosphatase diluted 1:5,000 in blocking solution, 50 ml per well for 1 h. Following a final six PBS-T washes, and two PBS washes, plates were developed and optical density read at 405 nm as previously described 21 . Crystallization, data collection and data processing of PfRH5 complexes. Crystallization was achieved using vapour diffusion in sitting drops. A TTP Labtech Mosquito LCP robot was employed to mix 100 nl of each protein complex at 8 mg ml 21 with 100 nl of well solutions from commercially available crystal screens. Crystals were first obtained in conditions from the Proplex (RH5DNL-basigin), JCSG1 (RH5DNL-9AD4) and Morpheus (RH5DNL-QA1) crystal screens (Molecular Dimensions). The well solution for PfRH5DNL-basigin was 0.2 M lithium sulphate, 0.1 M MES (pH 6.0), and 20% (w/v) PEG 4000. For PfRH5DNL-9AD4, the well solution was 24% (w/v) PEG 1500 and 20% (v/v) glycerol. PfRH5DNL-QA1 was crystallized in a 0.12 M mix of 1,6-hexanediol, 1-butanol, 1,2-propanediol, 2-propanol, 1,4-butanediol, 1,3-propanediol; 0.1 M MES-imidazole (pH 6.5); 20% (w/v) PEG 550 MME; and 10% (w/v) PEG 20,000. Crystals were obtained at 4 uC for PfRH5DNLbasigin and PfRH5DNL-9AD4, and at 18 uC for PfRH5DNL-QA1. Crystal seeds were generated by adding crystals in well solution to a Seed Bead (Hampton Research) and vortexing for 15 s. New crystal drops were then set up by mixing 100 nl of 8 mg ml 21 protein complex, 50 nl of well solution, 50 nl of seeds, and 50 nl of Silver Bullets or Silver Bullets Bio additives (Hampton Research).
RH5DNL-basigin crystals were cryoprotected by transfer into well solution supplemented with 25% ethylene glycol, then cryocooled by plunging into nitrogen. PfRH5DNL-9AD4 crystals were directly cryocooled. PfRH5DNL-QA1 crystals were cryoprotected in well solution with a total of 32% (w/v) PEG 550 MME and 16% (w/v) PEG 20,000 before cryocooling.
Data were collected at the Diamond Light Source, on beamline I04-1 for the PfRH5DNL-basigin complex (wavelength 0.92 Å ), and on beamline I04 for both PfRH5DNL-Fab complexes (wavelength 0.97949 Å ). Data reduction was performed using iMosflm 22, 23 and scala 24 from the CCP4 processing suite 25 . A composite of the light chain from PDB entry 3QQ9 and the heavy chain from 3HR5 was used as LETTER RESEARCH a molecular replacement model for 9AD4 in Phaser 26 . Density modification was performed with PARROT 27 . Buccaneer 28 was employed to build helices into initial PfRH5DNL density, initiating a cycle of model building and refinement using REFMAC 29 , BUSTER 30 , and Coot 31 . PfRH5DNL was used as a molecular replacement model in Phaser 26 , together with basigin (PDB code 3B5H) for the PfRH5DNLbasigin structure, or with a composite of the heavy chain from 2ZN9 and the light chain from 1I7Z for the PfRH5DNL-QA1 structure. Refinement was accomplished with BUSTER 30 . Ramachandran statistics, determined using PROCHECK 32 , were as follows: for PfRH5DNL-basigin, 93% of residues fell in the allowed regions and 7% in the additional allowed region; for PfRH5DNL-9AD4, 93.9% were in the allowed region, 5.8% were in the additional allowed region, and 0.2% were in the generously allowed region; and for PfRH5DNL-QA1, 86.0% were in the allowed region, 13.3% were in the additional allowed region, and 0.7% were in the generously allowed region. There were no residues in the disallowed region of the Ramachandran plot in any of the structures. Alignment of RH protein sequences. Sequences of P. falciparum RH1, RH4, RH2a, RH2b, and RH3; P. vivax RBP-1 and RBP-2; P. reichenowi RH5; and P. yoelii Py01365 were aligned against PfRH5 using the Clustal Omega server 33 , and an alignment figure generated with ESPript 34 . The homologous portion of each sequence was then threaded onto the PfRH5 structure using the Phyre2 server 35 . Small-angle X-ray scattering data collection and processing. Small-angle X-ray scattering (SAXS) data were collected at beamline BM29 at the European Synchrotron Radiation Facility (ESRF, Grenoble, France). Scattering was detected using a Pilatus image reader at 20 uC.
Full-length PfRH5-basigin, PfRH5-QA1 and PfRH5-QA5 complexes were prepared by mixing the individual proteins in equimolar amounts, and gel filtering on a Superdex 200 16/60 column in 20 mM HEPES (pH 7.5), 150 mM NaCl. PfRH5-9AD4 samples were prepared by mixing PfRH5 and 9AD4 in equimolar amounts for 10 min. 60-ml samples were prepared in serial dilutions between 0.2 and 2.0 mg ml 21 .
Ten consecutive frames of 10 s each were recorded for each protein sample, with buffer samples measured in between. The frames were inspected for any evidence of radiation damage, and any affected images were excluded from further processing. Data were normalized to the intensity of the incident beam, images were averaged, and buffer scattering subtracted using PRIMUS 36, 37 . Guinier plots were inspected to assess the presence of aggregation 38 . Composite curves were generated by scaling and merging appropriate data sets. The radius of gyration (R g ) was determined from the Guinier plot using AutoRg 37 . The distance distribution function (P(r)) was obtained by indirect Fourier transform, generating an estimate of the maximum particle dimension (D max ) and the Porod volume of the hydrated particle 37, 39 . An estimate of the molecular weight was obtained by dividing the Porod volume by 1.7. Twenty ab initio shape reconstructions were generated with DAMMIF 40 and averaged with DAMAVER 41 . The normalized spatial discrepancy (NSD) parameter was used to diagnose the similarity of the reconstructions 42 . SITUS and SCULPTOR 43 were used to dock atomic structures into the SAXS envelopes. Analytical ultracentrifugation. Analytical ultracentrifugation experiments were carried out using a Beckman An-60 Ti rotor in a Beckman Optima XL-1 analytical ultracentrifuge at 20 uC. Samples were prepared at concentrations of 0.5-1.0 mg ml 21 in 20 mM HEPES (pH 7.5), and 150 mM NaCl.
The samples for sedimentation velocity experiments were full-length PfRH5, basigin, and a PfRH5-basigin complex prepared by gel filtration. Scans were recorded using interference optics. Multiple scans were fitted to a continuous size distribution using SEDFIT 44, 45 . The buffer density and viscosity were calculated with SEDNTERP 46 . The sample partial specific volumes were estimated from the amino acid sequences, also using SEDNTERP.
During the time course of a sedimentation equilibrium experiment, degradation of full-length PfRH5 was observed. Therefore experiments were performed using PfRH5DN. Basigin, PfRH5DN and a gel-filtered PfRH5DN-basigin complex were analysed at 22 mM, 9 mM, and 9 mM, respectively. The run proceeded for 20 h at different speeds and scans recorded the ultraviolet absorbance at 280 nm. The buffer density and viscosity, together with sample partial specific volumes, were calculated as above 46 . The data were fitted to an ideal monodisperse model using SEDPHAT 47 , with the assumption that at concentrations of ,10 times the K D , PfRH5DN is fully complexed with basigin.
Extended Data Figure 1 | PfRH5 disorder predictions and structural alignment. a, Long-range disorder was predicted by POODLE-L 19 and was used to determine domain boundaries for the PfRH5DNL crystallization construct. The disorder predictions are shown above the sequence of PfRH5, with values of .0.5 indicative of disorder. The residues visible in the PfRH5DNL crystal structure are shown below the PfRH5 sequence as secondary structure elements (sheets as blue arrows, and helices as tubes in rainbow colouring) linked by blue lines. The missing loop (248-296) is shown as a break in the blue line. The secretion signal sequence is indicated (black underline). b, Two copies of PfRH5 from the PfRH5-basigin structure (red and orange), two copies from the PfRH5-QA1 structure (blue and cyan), and one copy from PfRH5-9AD4 (green) structure were aligned using Coot 31 , giving an r.m.s.d. of 1.7 Å . The C terminus and the loop between helices 4 and 5 were the only regions showing significant differences. For the remaining 95% of PfRH5, the r.m.s.d. is 0.9 Å .
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Extended Data Figure 5 | Location of PfRH5 polymorphisms, and residues of PfRH5 and basigin implicated in host tropism. a, b, Indicated are the locations of PfRH5 SNPs that are common (10% frequency or greater; red sticks) or uncommon (blue sticks) among 227 field isolates 7, 8, 12 , as well as additional SNPs observed in lab strains (green sticks) 15, 16 . b, Basigin (blue) is shown in addition to PfRH5 (yellow). SNPs Y203, I204, N347, Y358 and E362 are localized in or near the PfRH5-basigin interface. Not visible in this orientation is lab strain polymorphism K429. c, Highlighted are basigin residues F27, Q100 and H102 (orange sticks). Mutation of F27 or Q100, or an insertion adjacent to H102, all change the affinity for PfRH5 17 . Also shown are two SNPs of PfRH5, namely N347 and I204 (pink sticks), found in the PfRH5basigin binding interface and linked to the strain's ability to invade Aotus monkey erythrocytes 15 .
